TNGX

Tango Therapeutics stock has soared this year on its pancreatic cancer treatment combination with Revolution Medicines.

Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 11 Best Day Trading Stocks to Buy Now. Financial firm Mizuho raised its share price target for Tango Therapeutics Inc. (NASDAQ:TNGX) on March 11th. It slightly adjusted the target to $20 from $19 and kept an Outperform rating on the stock. Mizuho’s coverage came after the precision oncology company reported its earnings for the fourth quarter and full year 2025. The results saw Tango Therapeutics Inc. (NASDAQ:TNGX) post $343 million in cash and outline that it expected to have runway beyond 2028. The firm also outlined that it was on track to start a study for pancreatic cancer treatment and added that it had entered into an agreement for evaluating a molecular glue in a clinical trial. Wedbush also discussed Tango Therapeutics Inc. (NASDAQ:TNGX)’s shares in March. It raised the share price target to $19 from $15 and kept an Outperform rating on the stock. The financial firm outlined that it expected Tango Therapeutics Inc. (NASDAQ:TNGX)’s vopimetostat treatment for pancreatic cancer to enter its first major study in 2026. Tango Therapeutics Inc. (NASDAQ:TNGX) is a biotechnology company focusing on cancer treatments. It is headquartered in Boston, Massachusetts. While we acknowledge the potential of TNGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. Follow Insider Monkey on Google News.

Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New clinical supply agreement with Erasca, plus ongoing Revolution Medicines collaboration, supports potential of vopimetostat as the preferred PRMT5 inhibitor for combination with RAS targeted therapies in oncology Cash position of $343 million as of December 31, 2025, with runway into 2028 beyond anticipated key data inflection points BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business highlights. “We enter 2026 with a clear focus on execution, building on the significant progress achieved across our development portfolio in 2025,” said Malte Peters, M.D., President and CEO of Tango Therapeutics. “Our lead clinical program, vopimetostat, continues to demonstrate best-in-class potential, and we are on track to launch our first pivotal study in 2L pancreatic cancer this year. Strong enrollment continues in the combination study with Revolution Medicines’ RAS(ON) inhibitors, and we are encouraged by the early safety and efficacy data. Given the differentiated profile of vopimetostat enabling the potential for efficacious and tolerable RAS inhibitor combinations, we have entered into a supply agreement with Erasca for its pan-RAS molecular glue ERAS-0015 to further explore the potential of vopimetostat as the preferred PRMT5 inhibitor for combination therapy in pancreatic cancer and other tumor types. These activities are supported by our robust balance sheet, which provides cash runway into 2028, and plans to allocate capital with discipline in areas where we are best positioned to create significant value for patients.” Clinical Pipeline Updates Vopimetostat – MTAP Selective Once-Daily PRMT5 Inhibitor Pivotal Study in Pancreatic Cancer. The company is on track to initiate a pivotal study for vopimetostat monotherapy in 2L MTAP-del pancreatic cancer, with initiation anticipated in 2026. Phase 1/2 RAS(ON) Inhibitors Combination Study. Robust enrollment in the vopimetostat + RAS(ON) inhibitors combinat...

– Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months– – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 – – 49% ORR and mPFS 9.1 months in histology selective cohort of multiple late line, difficult to treat cancers provide further evidence of strong activity – – $225 million in gross proceeds from October 2025 financing extends cash runway into 2028 – BOSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today reported financial results for the third quarter ended September 30, 2025, and provided business highlights. “We are wrapping up 2025 with significant momentum, supported by our recent disclosure of vopimetostat clinical data, supporting the potential of this compound to be a turning point for treatment of multiple difficult-to-treat MTAP-del cancers, beginning with pancreatic cancer,” said Barbara Weber, M.D., President and CEO of Tango Therapeutics. “The data we presented support our planned pivotal trial in 2L MTAP-del pancreatic cancer with an anticipated study start in 2026. Our ongoing study of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors is also progressing well and we look forward to sharing an update from that study in 2026. Our clinical development plans are supported by our strong balance sheet, reinforced by our recent $225 million financing, which extends our cash runway into 2028. Additionally, we expect a strong cadence of value creating milestones in 2026.” Pipeline Update Vopimetostat (TNG462) Clinical Update In October 2025, vopimetostat clinical data were announced in a corporate presentation. With a mPFS of 7.2 months, the data support the planned pivotal study in 2L MTAP-del pancreatic cancer anticipated to start in 2026. There is robust enrollment in the ongoing combination study of vopimetostat + RAS(ON) inhibitors in 2L+ MTAP-del, RAS-mut pancreatic and lung cancer patients. Vopimetostat in combination with either daraxonrasib or zoldonrasib have been well-tolerated to date with exposures in the active range for each compound. Initial data from the Phase 1/2 study are anticipated in 2026. The lung cancer cohort of the phase 1/2 single agent v...

Tango Therapeutics, Inc. (TNGX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +1,200.00%. A quarter ago, it was expected that this company would post a loss of $0.35 per share when it actually produced a loss of $0.35, delivering no surprise. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Tango Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $53.81 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 23.20%. This compares to year-ago revenues of $11.61 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Tango Therapeutics shares have added about 159.2% since the beginning of the year versus the S&P 500's gain of 16.5%. While Tango Therapeutics has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Tango Therapeutics was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list...

This article first appeared on GuruFocus. Tango Therapeutics Inc (NASDAQ:TNGX) is set to release its Q3 2025 earnings on Nov 4, 2025. The consensus estimate for Q3 2025 revenue is $37.14 million, and the earnings are expected to come in at -$0.05 per share. The full year 2025's revenue is expected to be $49.66 million and the earnings are expected to be -$1.09 per share. More detailed estimate data can be found on the Forecast page. Warning! GuruFocus has detected 5 Warning Signs with TNGX. Is TNGX fairly valued? Test your thesis with our free DCF calculator. Revenue estimates for Tango Therapeutics Inc (NASDAQ:TNGX) have increased from $28.43 million to $49.66 million for the full year 2025. However, for 2026, they have declined from $25.77 million to $13.97 million over the past 90 days. Earnings estimates for the full year 2025 have improved from -$1.39 per share to -$1.09 per share. For 2026, earnings estimates have slightly increased from -$1.35 per share to -$1.34 per share over the past 90 days. In the previous quarter ending 2025-06-30, Tango Therapeutics Inc's (NASDAQ:TNGX) actual revenue was $3.18 million, which missed analysts' revenue expectations of $6.68 million by -52.37%. Tango Therapeutics Inc's (NASDAQ:TNGX) actual earnings were -$0.35 per share, which beat analysts' earnings expectations of -$0.36 per share by 3.85%. After releasing the results, Tango Therapeutics Inc (NASDAQ:TNGX) was up by 4.86% in one day. Based on the one-year price targets offered by 8 analysts, the average target price for Tango Therapeutics Inc (NASDAQ:TNGX) is $12.13 with a high estimate of $15.00 and a low estimate of $8.00. The average target implies an upside of 49.51% from the current price of $8.11. Based on GuruFocus estimates, the estimated GF Value for Tango Therapeutics Inc (NASDAQ:TNGX) in one year is $2.78, suggesting a downside of -65.72% from the current price of $8.11. Based on the consensus recommendation from 9 brokerage firms, Tango Therapeutics Inc's (NASDAQ:TNGX) average brokerage recommendation is currently 1.6, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

On October 23, 2025, Tango Therapeutics announced positive data from its Phase 1/2 trial of Vopimetostat (TNG462) in MTAP-deleted cancers and completed both a US$209.99 million follow-on equity offering and a US$15 million private placement led by Nextech Invest Ltd. This combination of encouraging clinical trial results and successful capital raises marks a pivotal step for Tango's research progress and future funding capability. We'll explore how the clinical progress with Vopimetostat shapes Tango Therapeutics' investment narrative and overall outlook. The end of cancer? These 28 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. To be a Tango Therapeutics shareholder, you need to believe in the company’s ability to transform its strong scientific pipeline into commercial success, despite ongoing unprofitability, large cash burn, and aggressive valuation multiples. The recent announcement of positive Phase 1/2 data on Vopimetostat and the completion of a sizeable US$210 million equity offering, plus an additional US$15 million private placement, may shift the short-term narrative. Previously, the biggest catalysts hinged on clinical progress and sufficient funding, while risks focused on dilution and rising losses. With more capital on hand and promising clinical data, immediate funding risk is reduced, and attention now pivots toward upcoming trial milestones and the coming end of lock-up agreements in December. The latest news strengthens Tango’s ability to advance its research, but persistent losses and dilution risk remain significant factors to watch. Yet, the potential impact of those lock-up expiries could catch some by surprise. Upon reviewing our latest valuation report, Tango Therapeutics' share price might be too optimistic. The Simply Wall St Community’s two fair value estimates for Tango Therapeutics range from US$10.00 to US$12.71 per share. While these span a relatively narrow band, the broader market remains focused on clinical milestones and capital needs. Exploring these alternative viewpoints can be useful as the company’s financial and research balance continues to face real-world challenges. Explore 2 other fair value estimates on Tango Therapeutics - why the stock might be worth as much as 63% more than the current price! Disagree with this assessment? Cr...

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com. Investors and Media: Elizabeth Hickin [email protected] [email protected]

Explore Tango Therapeutics's Fair Values from the Community and select yours Revenue: US$3.18m (down 84% from 2Q 2024). Net loss: US$38.9m (loss widened by 52% from 2Q 2024). US$0.35 loss per share (further deteriorated from US$0.24 loss in 2Q 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 53%. Earnings per share (EPS) also missed analyst estimates by 1.2%. Looking ahead, revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are up 7.0% from a week ago. It is worth noting though that we have found 2 warning signs for Tango Therapeutics (1 doesn't sit too well with us!) that you need to take into consideration. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

– First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors – – First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5 inhibitor in development for glioblastoma – BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today reported financial results for the second quarter ended June 30, 2025, and provided business highlights. “TNG462 has the potential to be a best-in-class PRMT5 inhibitor for the treatment of MTAP-del pancreatic and lung cancers, and we look forward to sharing data that support our conviction later this year,” said Barbara Weber, M.D., President and CEO of Tango Therapeutics. “We plan to present efficacy and tolerability data from the ongoing TNG462 monotherapy Phase 1/2 study that will inform the initiation of a registrational study in pancreatic cancer next year and our development strategy in lung cancer. In addition, we are now enrolling patients in the TNG462 combination clinical trial with Revolution Medicines’ RAS(ON) inhibitors. Preclinical data support the potential for these combinations to be an important new therapy for RAS-mut, MTAP-del cancers, and reinforce our belief that TNG462 has the potential to play a major role in treating patients with MTAP-del cancers.” Pipeline Update TNG462, a potentially best-in-class MTA-cooperative PRMT5 inhibitor In June, the first patient was treated in a combination trial (NCT06922591) with TNG462 and RAS(ON) multi-selective inhibitor, daraxonrasib, and RAS(ON) G12D-selective inhibitor, zoldonrasib, (Revolution Medicines). The combination of TNG462 with each of these molecules generated deep, durable tumor responses in preclinical models. A clinical data update on the TNG462 Phase 1/2 monotherapy trial is expected in the second half of this year. This update is anticipated to provide sufficient information to inform the initiation of a registrational trial in pancreatic cancer next year and our development strategy for lung cancer. The Phase 1/2 dose expansion trial is ongoing and TNG462 continues to be very well-tolerated at 250mg once-daily (QD) and below. Safety and tolerability data as of June 16, 2025 are consistent with a best-in-class profile at 250 mg QD, t...

Tango Therapeutics Inc (NASDAQ:TNGX) is set to release its Q2 2025 earnings on Aug 5, 2025. The consensus estimate for Q2 2025 revenue is $6.68 million, and the earnings are expected to come in at -$0.36 per share. The full-year 2025's revenue is expected to be $28.43 million, and the earnings are expected to be -$1.39 per share. More detailed estimate data can be found on the Forecast page. Warning! GuruFocus has detected 4 Warning Signs with TNGX. Over the past 90 days, revenue estimates for Tango Therapeutics Inc (NASDAQ:TNGX) have declined from $28.96 million to $28.43 million for the full year 2025, while they have increased from $24.83 million to $25.77 million for 2026. Similarly, earnings estimates have declined from -$1.36 per share to -$1.39 per share for the full year 2025, and increased from -$1.39 per share to -$1.35 per share for 2026. In the previous quarter of 2025-03-31, Tango Therapeutics Inc's (NASDAQ:TNGX) actual revenue was $5.39 million, which missed analysts' revenue expectations of $6.69 million by -19.45%. Tango Therapeutics Inc's (NASDAQ:TNGX) actual earnings were -$0.36 per share, which missed analysts' earnings expectations of -$0.35 per share by -2.86%. After releasing the results, Tango Therapeutics Inc (NASDAQ:TNGX) was up by 14.91% in one day. Based on the one-year price targets offered by 6 analysts, the average target price for Tango Therapeutics Inc (NASDAQ:TNGX) is $10.00, with a high estimate of $13.00 and a low estimate of $8.00. The average target implies an upside of 53.14% from the current price of $6.53. Based on GuruFocus estimates, the estimated GF Value for Tango Therapeutics Inc (NASDAQ:TNGX) in one year is $4.31, suggesting a downside of -34% from the current price of $6.53. Based on the consensus recommendation from 8 brokerage firms, Tango Therapeutics Inc's (NASDAQ:TNGX) average brokerage recommendation is currently 1.5, indicating a "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell. This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Tango Therapeutics, Inc. (TNGX) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 5. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. This company is expected to post quarterly loss of $0.35 per share in its upcoming report, which represents a year-over-year change of -45.8%. Revenues are expected to be $6.19 million, down 68.9% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 1.62% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power i...